OCTOBER 13, 2025 – Johnson & Johnson, a global leader in eye health, is pleased to announce that the TECNIS ODYSSEY IOL, the fastest-growing PC-IOL in the U.S.,^ has been implanted in 100,000 eyes* in the U.S. since launch in 2024. Johnson & Johnson will present the TECNIS ODYSSEY IOL, innovative advancements in laser cataract surgery and phacoemulsification, and fresh insights from investigator-initiated studies at the 2025 AAO Annual Meeting, October 18-20. The new clinical data will be presented validating surgical outcomes and patient satisfaction across the full cataract and refractive surgery portfolio—reinforcing confidence in procedural efficacy and patient-centered care.
INNOVATION
TECNIS ODYSSEY IOL delivers over 95% of light utilization,1 supporting image quality2,3,4 and visual acuity, giving patients sharp, clear vision with minimal distortion in real-world settings.5,6 Additionally, TECNIS ODYSSEY IOL delivers superior image contrast day and night, outperforming the leading competitor monofocal IOL in low-light conditions.2,3,7≠ Together, these attributes position TECNIS ODYSSEY IOL as a PC-IOL of choice for surgeons seeking to give patients uncompromising quality across the full visual range. TECNIS ODYSSEY IOL also provides:
· Enhanced tolerance to refractive error8 €
· Optimized dysphotopsia profile9 €
· Unmatched range of vision 10 ** ¶
SURGICAL EQUIPMENT PORTFOLIO
Historically, as of 2023, CATALYS Precision Laser System has carried the #1 LCS utilization rate in the industry.11 CATALYS System cOS 7.0 will be showcased at the conference, which includes integration with a biometer to enable seamless pre-operative measurements and astigmatism management capabilities. Surgeons who’ve used the cOS 7.0 reported 100% confidence in their ability to treat more patients with ease and precision. The upgrade is currently available in the US.12
VERITAS Vision System’s Hybrid Fluidics Technology delivers exceptional chamber stability through the combination of an Advanced Tubing System (ATS), Dual Pump, and Advanced Infusion.13,14,15,16,17
Surgeons on site will gain firsthand insights into the equipment’s superior control, advanced capabilities, and ease of use through a wet lab experience.
DATA
Investigator-initiated data shows positive outcomes and satisfaction rates across the Johnson & Johnson ophthalmic portfolio.
· Optical Phenomena and Tolerance to Simulated Astigmatism of a Violet light filtering Diffractive Full-Range Vision Intraocular Lens; 30082042; Karolinne Rocha, MD, et. Al.
o A study evaluating the tolerance to induced astigmatism and visual symptoms in eyes implanted with a diffractive full-range of vision (FVR) IOL with a violet-light filter (TECNIS ODYSSEY IOL) found:
§ The new FVR IOL (TECNIS ODYSSEY IOL) exhibited satisfactory tolerance to induced astigmatism.
· Clinical and Patient-Reported Outcomes of Mild Glaucoma Patients Implanted with Extended Depth of Focus IOLs; 30083549; Zarmeena Vendal, MD.
o A study evaluating clinical and patient-reported outcomes following bilateral implantation of TECNIS Symfony OptiBlue in patients diagnosed as glaucoma suspects or with mild glaucoma found:
- All subjects were 20/30 or better at all distances,
- Spectacle independent at all distance and intermediate,
- Suggesting violet-light filtering EDOF IOLs can provide glaucoma patients with the opportunity to enjoy good vision at all distances.
Johnson & Johnson can be found at booth #2509.
INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS ODYSSEY™ IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODEL DRN00V AND TECNIS ODYSSEY™ TORIC II IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODELS DRT150, DRT225, DRT300, DRT375
Rx Only
INDICATIONS FOR USE:
The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Odyssey™ IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only.
PRECAUTIONS
1. This is a single use device. Do not resterilize the lens or the delivery system. Most sterilizers are not equipped to sterilize the soft acrylic material and the preloaded inserter material without producing undesirable side effects.
2. Do not store the device in direct sunlight or at a temperature under 41°F (5°C) or over 95°F (35°C).
3. Do not autoclave the delivery system.
4. Do not advance the lens unless ready for lens implantation.
5. The contents are sterile unless the package is opened or damaged.
6. The recommended temperature for implanting the lens is at least 63°F (17°C).
7. The use of balanced salt solution or ophthalmic viscosurgical devices (OVDs), is required when using the delivery system. For optimal performance when using OVD, use the HEALON™ family of OVDs. The use of balanced salt solution with additives has not been studied for this product.
8. Do not use if the delivery system has been dropped or if any part was inadvertently struck while outside the shipping box. The sterility of the delivery system and/ or the lens may have been compromised.
9. When performing refraction in patients implanted with the lens, interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended.
10. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design.
11. Recent contact lens usage may affect the patient’s refraction; therefore, in contact lens wearers, surgeons should establish corneal stability without contact lenses prior to determining IOL power.
12. The surgeon should target emmetropia as this lens is designed for optimum visual performance when emmetropia is achieved.
13. Care should be taken to achieve centration of the intraocular lens in the capsular bag.
14. Prior to surgery, the surgeon must inform prospective patients of the possible risks and benefits associated with the use of the device and provide them a copy of the patient information brochure.
15. Children under the age of 2 years are not suitable candidates for intraocular lenses.
16. The lens should not be placed in the ciliary sulcus.
17. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the toric lens with the intended axis of placement.
18. The TECNIS™ Toric IOL Calculator includes a feature that accounts for posterior corneal astigmatism (PCA). The PCA is based on an algorithm that combines published literature (Koch, et al., 2012) and a retrospective analysis of data from a TECNIS™ Toric multi-center clinical study. The PCA algorithm for the selection of appropriate cylinder power and axis of implantation was not assessed in the prospective TECNIS™ Toric IOL U.S. IDE study and may yield results different from those in the TECNIS Odyssey™ Toric II IOL labeling. Please refer to the TECNIS™ Toric IOL Calculator user manual for more information.
19. The use of methods other than the TECNIS™ Toric IOL Calculator to select cylinder power and appropriate axis of implantation were not assessed in the TECNIS™ Toric IOL U.S. IDE study and may not yield similar results. Accurate keratometry and biometry, in addition to the use of the TECNIS™ Toric IOL Calculator (www.TecnisToricCalc.com) are recommended to achieve optimal visual outcomes for the toric lens.
20. All preoperative surgical parameters are important when choosing a toric lens for implantation, including preoperative keratometric cylinder (magnitude and axis), incision location, the surgeon’s estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism.The effectiveness of TECNIS Odyssey™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism <1.0 diopter has not been demonstrated.
21. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Odyssey™ and TECNIS Odyssey™ Toric II IOLs, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower astigmatism.
22. All corneal incisions were placed temporally in the TECNIS™ Toric IOL U.S. IDE study. If the surgeon chooses to place the incision at a different location, outcomes may be different from those obtained for the TECNIS™ Toric IOL. Note that the TECNIS™ Toric IOL Calculator incorporates the surgeon’s estimated SIA and incision location when providing IOL options.
23. Do not reuse.
24. The safety and effectiveness of the TECNIS Odyssey™ IOL and the TECNIS Odyssey™ Toric II IOL have not been substantiated in patients under the age of 22 or those with preexisting ocular conditions and intraoperative complications, including those specified in the Warnings and Precautions, such as pupil abnormalities, prior corneal refractive or intraocular surgery, acute or chronic ophthalmic diseases or conditions (see below for examples).
25. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the benefit/risk ratio before implanting a lens in a patient with one or more of these conditions.
Before Surgery
· Pupil abnormalities
· Prior corneal refractive or intraocular surgery
· Choroidal hemorrhage
· Chronic severe uveitis
· Concomitant severe eye disease
· Extremely shallow anterior chamber
· Medically uncontrolled glaucoma
· Microphthalmos
· Non-age-related cataract
· Proliferative diabetic retinopathy (severe)
· Severe corneal dystrophy
· Severe optic nerve atrophy
· Irregular corneal astigmatism
· Amblyopia
· Macular disease
· Pregnancy
During Surgery
· Excessive vitreous loss
· Non-circular capsulotomy/capsulorhexis
· The presence of radial tears known or suspected at the time of surgery
· Situations in which the integrity of the circular capsulotomy/capsulorhexis cannot be confirmed by direct visualization
· Cataract extraction by techniques other than phacoemulsification or liquefaction
· Capsular rupture
· Significant anterior chamber hyphema
· Uncontrollable positive intraocular pressure
· Zonular damage
26. Potential complications generally associated with cataract surgery include, but are not limited to: endophthalmitis/intraocular infection, hypopyon, hyphema, IOL dislocation, persistent cystoid macular edema, pupillary block, retinal detachment/tear, persistent corneal stromal edema, persistent uveitis, persistent raised intraocular pressure (IOP) requiring treatment (e.g., AC tap), retained lens material, or toxic anterior segment syndrome, or any other adverse event that leads to permanent visual impairment or requires surgical or medical intervention to prevent permanent visual impairment. Adverse events that may be associated with use of the device include: IOL dislocation, tilt or decentration, visual symptoms requiring lens removal, residual refractive error, secondary surgical intervention (including IOL repositioning or removal).
27. Do not leave the lens in a folded position more than 10 minutes.
28. When the delivery system is used improperly, the lens may not be delivered properly, (i.e., haptics may be broken). Please refer to the specific instructions for use provided.
WARNINGS
1. Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients with:
a. Recurrent severe anterior or posterior segment inflammation of unknown etiology
b. Posterior segment diseases of which monitoring or treatment ability may be limited by an intraocular lens
c. Surgical difficulties at the time of cataract extraction and/or intraocular lens implantation that might increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled positive pressure, or significant vitreous prolapse or loss)
d. Compromised posterior capsule or zonules due to previous trauma or developmental defect in which appropriate support of the IOL is not possible
e. Risk of damage to the endothelium during implantation
f. Suspected microbial infection
g. Congenital bilateral cataracts
h. Previous history of, or a predisposition to, retinal detachment
i. Potentially good vision in only one eye
j. Medically uncontrollable glaucoma
k. Corneal endothelial dystrophy
l. Proliferative diabetic retinopathy.
2. Patients should have well-defined visual needs and be informed of possible visual effects (such as a perception of halo, starbursts or glare around lights), which may be expected in nighttime or poor visibility conditions. Patients may perceive these visual effects as bothersome, which, on rare occasions, may be significant enough for the patient to request removal of the IOL.
3. A reduction in contrast sensitivity compared to an aspheric monofocal IOL may be experienced by some patients under certain conditions. The physician should carefully weigh the potential risks and benefits for each patient, with special consideration of potential visual problems before implanting the lens in patients including those with macular disease, amblyopia, corneal irregularities, or other ocular disease that may cause present or future reduction in acuity or contrast sensitivity, and should fully inform the patient of the potential for reduced contrast sensitivity and to exercise caution when driving at night or in poor visibility conditions after implantation.
4. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of reducing spectacle wear.
5. Rotation of the toric lens from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible prior to lens encapsulation.
6. Do not attempt to disassemble, modify or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design.
7. Do not use if the cartridge of the delivery system is cracked or split prior to implantation.
8. Do not implant the lens if the rod tip does not advance the lens or if it is jammed in the delivery system.
9. Do not stop, reverse or advance the plunger too slowly (for example more than 1 second) during initial IOL advancement. Doing so may result in improper folding of the lens.
10. Do not advance the IOL from the Holding Position prior to fully hydrating the system. A minimum of 1 minute at the Holding Position is required to fully hydrate the system to prevent sticking and a potential scratch or crack to the IOL.
11. Do not advance the IOL from the Holding Position until ready for implantation. Interruptions during delivery may result in the IOL being scratched or cracked or stuck in the cartridge. Discard the device if the IOL has been advanced past the Holding Position but not delivered within 60 seconds.
12. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge.
13. Johnson & Johnson Surgical Vision, Inc. single-use medical devices are labeled with instructions for use and handling to minimize exposure to conditions which may compromise the product, patient, or the user. When used according to the directions for use, the delivery system minimizes the risk of infection and/or inflammation associated with contamination.
14. The reuse/resterilization/reprocessing of Johnson & Johnson Surgical Vision, Inc. single-use devices may result in physical damage to the medical device, failure of the medical device to perform as intended, and patient illness or injury due to infection, inflammation, and/or illness due to product contamination, transmission of infection, and lack of product sterility.
IMPORTANT INDICATIONS AND SAFETY INFORMATION for CATALYS® Precision Laser System
Reference the labeling for a complete listing of Important Indications and Safety Information.
INDICATIONS
The CATALYS® Precision Laser System is indicated for use in patients undergoing cataract surgery for removal of the crystalline lens. Intended uses in cataract surgery include anterior capsulotomy, phacofragmentation, and the creation of single plane and multi-plane arc cuts/incisions in the cornea, each of which may be performed either individually or consecutively during the same procedure.
CONTRAINDICATIONS
The CATALYS® System should not be used in patients with corneal ring and/or inlay implants, severe corneal opacities, corneal abnormalities, significant corneal edema or diminished aqueous clarity that obscures OCT imaging of the anterior lens capsule, patients younger than 22 years of age, descemetocele with impending corneal rupture, and any contraindications to cataract surgery.
ADVERSE EFFECTS
Complications associated with the CATALYS® System include mild Petechiae and subconjunctival hemorrhage due to vacuum pressure of the LIQUID OPTICS Interface suction ring. Potential complications and adverse events include those generally associated with the performance of capsulotomy and lens fragmentation, or creation of a partial-thickness or full-thickness cut or incision of the cornea
INDICATIONS AND IMPORTANT SAFETY INFORMATION for the VERITAS™ Vision System
Rx Only
INDICATIONS FOR USE: The VERITAS™ Vision System is a modular ophthalmic microsurgical
system that facilitates anterior segment (i.e., cataract) ophthalmic surgery. The modular design allows
the users to configure the system to meet their surgical requirements
IMPORTANT SAFETY INFORMATION: Risks and complications of cataract surgery may include
corneal burn. This device is only to be used by a trained licensed physician
ATTENTION: Reference the labeling for a complete listing of Indications and Important Safety
Information
INDICATION AND IMPORTANT SAFETY INFORMATION for the TECNIS Symfony™ OptiBlue™ Extended Range of Vision IOL with TECNIS SIMPLICITY™ Delivery System and TECNIS Symfony™ Toric II OptiBlue™ Extended Range of Vision IOL with TECNIS SIMPLICITY ™ Delivery SystemRx Only
INDICATIONS
The TECNIS SIMPLICITY ™ Delivery System is used to fold and assist in inserting the TECNIS Symfony™ OptiBlue™ Extended Range of Vision IOL, which is indicated for primary implantation for the visual correction of aphakia, in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only.
The TECNIS SIMPLICITY ™ Delivery System is used to fold and assist in inserting the TECNIS Symfony™ Toric II OptiBlue™ Extended Range of Vision IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The lenses are intended for capsular bag placement only.
WARNINGS
Patients with any of the conditions described in the Directions for Use may not be suitable candidates for an intraocular lens because the lens may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition, or may pose an unreasonable risk to the patient’s eyesight. Lenses should not be placed in the ciliary sulcus. The lens may cause a reduction in contrast sensitivity under certain conditions, compared to an aspheric monofocal IOL; fully inform the patient of this risk before implanting the lens. Special consideration should be made for patients with macular disease, amblyopia, corneal irregularities, or other ocular disease. Inform patients to exercise special caution when driving at night or in poor visibility conditions. Some visual effects may be expected due to the lens design, including a perception of halos, glare, or starbursts around lights under nighttime conditions. These will be bothersome or very bothersome in some people, particularly in low-illumination conditions, and on rare occasions may be significant enough that the patient may request removal of the IOL.
Rotation of the TECNIS Symfony™ Toric II OptiBlue™ IOLs away from their intended axis can reduce their astigmatic correction, and misalignment ˃30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible prior to lens encapsulation.
Do not attempt to disassemble, modify or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. Do not implant the lens if the rod tip does not advance the lens or if it is jammed in the delivery system. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes.
PRECAUTIONS
Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the optical design. Target emmetropia for optimum visual performance. Care should be taken to achieve IOL centration, as lens decentration may result in a patient experiencing visual disturbances under certain lighting conditions.
For the TECNIS Symfony™ Toric II OptiBlue™ IOL, variability in any preoperative surgical parameters (e.g., keratometric cylinder, incision location, estimated surgically induced astigmatism, or biometry) can influence patient outcomes. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case, to avoid lens rotation.
This is a single use device, do not resterilize the lens or the delivery system. Do not store the device in direct sunlight or at a temperature under 5°C (41°F) or over 35°C (95°F). Do not autoclave the delivery system. Do not advance the lens unless ready for lens implantation. The contents are sterile unless the package is opened or damaged. The recommended temperature for implanting the lens is at least 17°C (63°F). The use of balanced salt solution or viscoelastics is required when using the delivery system. Do not use if the delivery system has been dropped or if any part was inadvertently struck while outside the shipping box.
SERIOUS ADVERSE EVENTS
The most frequently reported serious adverse events during the clinical trial of the TECNIS Symfony™ lens were cystoid macular edema (2 eyes, 0.7%) and surgical reintervention (treatment injections for cystoid macular edema and endophthalmitis, 2 eyes, 0.7%). No lens-related adverse events occurred during the trial. Overall, 2.7% (4/148) of TECNIS Symfony™ subjects experienced serious adverse events during the study and 0% (0/148) experienced device-related or unanticipated events.
ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information.
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at
clearvisionforyou.com, follow
@JNJVision on X,
Johnson & Johnson | Vision on LinkedIn, and
@JNJVision on Facebook.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at
https://thenext.jnjmedtech.com. Follow us at
@JNJMedTech on LinkedIn.
©Johnson & Johnson and its affiliates 2025. All rights reserved.
Footnotes
*Launch to Date Implants. Data on File
^ Based on Market Scope’s estimated procedures Q2 report (Q4 2024 – current)
≠ Compared to leading competitor full range of vision IOLs based on bench testing (white light MTF at 50 c/mm measured for 3mm & 5mm pupil in the ACE model)
€ Compared to TECNIS SYNERGY™ based on bench testing**Continuous 20/25 or better based on pre-clinical bench testing for TECNIS Odyssey™¶Compared to PanOptix® based on bench testing and head-to-head clinical studies of parent lens
1 Weeber, Henk et al. Light Utilization of Diffractive Intraocular Lenses. Association for Research in Vision and Ophthalmology 2025. May 8 2025.
2 Data on File. DOF2023CT4007
3 Data on File. DOF2019OTH4002
4 Data on File. 2024DOF4033
5 Data on File. DOF2023CT4023
6 Data on File. DOF2023CT4050
7 Data on File. 2024DOF4033
8 Data on File. 2024DOF4003
9 Data on File. 2024DOF4005
10 DOF2023CT4023 Data on File. DOF2020CT4014 - Forte 1: A Comparative Clinical Evaluation of a New TECNISTM Presbyopia Correcting Intraocular Lens Against a PanOptix® Intraocular Lens - DEFOCUS CURVES AND VISUAL ACUITY RESULTS.
11 Data on file, 2021- 2023 US Market, 2024DOF4021
12 Johnson & Johnson, 2023. Data on file. LMR Survey - Phase II Results. DOF2023CT4047.
13 DOF2021MLT4002 Post-occlusion Surge Comparison Study
14 DOF2021OTH4005 VERITAS Vision System Features
15 DOF2021OTH4006 R&D Memo - Design intent for VERITAS Vision System
16 Z370584 VERITAS Operator Manual Rev E. page 3-4, 3-5, 3-6
17 Z370584 VERITAS Operator Manual Rev E. page 1-6, 1-8, 1-9, 3-7
Third party trademarks are the property of their respective owners.
Media contact:
Jamie Hall
Jhall41@its.jnj.com